Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

Creative Commons License

Elverdi T. , Eskazan A. E.

DRUG DESIGN DEVELOPMENT AND THERAPY, cilt.13, ss.1251-1258, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 13
  • Basım Tarihi: 2019
  • Doi Numarası: 10.2147/dddt.s134470
  • Sayfa Sayıları: ss.1251-1258


Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated. Therapeutic plasma exchange (PEX) is the mainstay of treatment of acquired TTP (aTTP), and with the introduction of PEX, the mortality rate declined dramatically below 20%. Although PEX together with corticosteroids are the backbone of the upfront management of patients with aTTP with successful outcomes, patients may remain refractory and/or relapse following an initial response to this treatment. There are some therapeutic options, which can be used among these patients, helping in improving outcomes of aTTP. Caplacizumab (formerly ALX-0081 or ALX-0681) is a humanized single-variable domain immunoglobulin that recognizes the human von Willebrand factor (vWF) A1 domain and inhibits the vWF platelet glycoprotein lb-alpha (GPI b-a) interaction. The drug was first developed for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous coronary intervention; however, drug development tbr this indication has been discontinued. Recently, caplacizumab received its first approval following Phase II TITAN and Phase III HERCULES trials in the European Union (EU) for the treatment of acute episode of aTTP in adult patients, in addition to PEX and immunosuppression. This review focuses on the use of caplacizumab as an emerging treatment option in patients with aTTP.